Idorsia Ltd., a Swiss biopharmaceutical company, is expanding into the United States by establishing commercial operations in Radnor, a Philadelphia suburb.
The company specializes in the discovery and development of small molecules and has a portfolio of drugs in its pipeline.
Idorsia Pharmaceuticals US will further develop and establish Idorsia’s budding global commercial organization, the company said. It will help patients benefit from the company’s new therapies.
The company will meet the changing needs of health care professionals, patients, and their families, it said.
Patricia Torr will serve as Idorsia US’s president and general manager.
“The U.S. healthcare system is complex and constantly evolving,” Torr said. “The need to bring innovative medicines to fill unmet needs for patients is as important as ever. Idorsia is committed to building our U.S. operations to bring creative solutions to the market based on our science and data. We have formed a talented and diverse leadership team to commercialize and realize the potential of our deep and broad pipeline. Each of the team members have exceptional experience of the pharma world, in their respective functional areas, as well as a strong entrepreneurial mindset. This combination will be critical to our success as we move a step closer to commercializing our first product in the U.S.”
Torr has more than two decades of pharmaceutical and biotech marketing and sales experience.